Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Emerging Biosimilars | Immunology | Inflectra | Wave 1 | US | 2017

Login to access report north_east
Contact sales account_box

Biosimilars│Emerging Biosimilars│Inflectra │U.S. Wave 1 is the first installment of a three-wave, syndicated report series, tracking physician perception and uptake of Pfizer/Celltrion’s Inflectra (biosimilar infliximab [infliximab-dyyb]) in the United States. The series is based on data collected at one, six, and twelve months’ postcommercial launch of Inflectra, with U.S.-based rheumatologists, gastroenterologists, and dermatologists. Along with awareness, familiarity, and perception of biosimilars in general, and Inflectra specifically, the research also explores physicians’ trial, adoption, and usage of Inflectra, including anticipated future trends and impact of its uptake on other immune biologics. Promotional efforts by Johnson & Johnson/Janssen and Pfizer are explored, as well as prescriber and nonprescriber profiles, and benchmarking comparisons against other available biosimilars.

Questions Answered in This Report:

  • Are U.S. physicians aware of Inflectra and its clinical development?
  • What are the drivers to prescribing Inflectra? What is the current level of Inflectra use, and how is that changing over time?
  • How has experience with Inflectra changed physicians’ opinion toward biosimilars?
  • Have physicians experienced pressure to prescribe Inflectra? In which settings/patients?
  • What promotional messages are sales representatives employing for Inflectra and Remicade?
  • How does initial formulary placement of Inflectra compare with other TNF-alpha inhibitors, and does this change over time?

Scope:

  • Markets covered: United States
  • Primary research: Survey of 91 U.S. rheumatologists, gastroenterologists, and dermatologists

Key Companies Mentioned:

  • Amgen
  • AbbVie
  • Celltrion
  • Johnson & Johnson/Janssen
  • Pfizer

Key Drugs Mentioned:

  • Remicade (infliximab)
  • Inflectra (infliximab-dyyb)
  • Enbrel (etanercept)
  • Humira (adalimumab)
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
north_east
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
north_east
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
north_east
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
north_east
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east